Studies related to Blood Pressure and Vitamin B2

Riboflavin Offers A Targeted Strategy For Managing Hypertension In Patients With The MTHFR 677TT Genotype: A 4-y Follow-up

Effect Decrease
Trial Design Cohort
Trial Length 6+ Months
Number of Subjects 88
Sex Both Genders
Age Range 45-64
Body Types Overweight
Notes for this study:
In a four year followup to a study using 1.6mg riboflavin daily in subjects who were hypertensive and MTHFR 677TT homozygous, it was found that continued usage of riboflavin for the four years afterwards was able to reduce both systolic and diastolic blood pressure.

Although the study broke down analysis into different genomic groups, a placebo control in the same group (MTHFR 677TT) was not used in this followup.

Full details on all 3 studies are available to Examine Members. Try out the Examine Membership with a 14-day free trial.

Already a Member? Log in now to access.